Skip to main content

Table 1 Patients’ background before administration of recombinant thrombomodulin

From: Administration of recombinant thrombomodulin before progression of disease causing disseminated intravascular coagulation might be better compared with administration after progression of disease

  Group S (n = 57) Group NS (n = 44) pvalue
Age, years, mean ± SD 68 ± 17 75 ± 11 0.036
Height, cm, mean ± SD 157 ± 8 157 ± 8 0.71
Weight, kg, mean ± SD 49 ± 10 58 ± 12 <0.001
BMI, kg/m2, mean ± SD 20 ± 4 23 ± 4 <0.001
Gender, female, n 27 10 0.011
Infection-induced DIC, n 48 38 0.76
Intra-abdominal, n 29 24  
Lung, n 9 10  
Urinary, n 3 0  
Others, n 7 4  
Non-infection-induced DIC, n 9 6 0.34
Obstetric, n 2 0  
Intestinal ischemia, n 2 3  
Others, n 5 3  
Heart disease, n 12 15 0.14
Diabetes mellitus, n 15 16 0.27
Hypertension, n 30 22 0.79
Smoking, n 19 22 0.091
  1. BMI body mass index, DIC disseminated intravascular coagulation.